NCT04447261View on ClinicalTrials.gov

A Study to Test How Well Different Doses of BI 1356225 Are Tolerated by Men and Women With Obesity or Overweight

PHASE1CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

June 30, 2020

Primary Completion Date

April 25, 2021

Study Completion Date

April 25, 2021

Conditions
Obesity
Interventions
DRUG

BI 1356225

BI 1356225

DRUG

Placebo

Placebo

Trial Locations (1)

68167

CRS Clinical Research Services Mannheim GmbH, Mannheim

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04447261 - A Study to Test How Well Different Doses of BI 1356225 Are Tolerated by Men and Women With Obesity or Overweight | Biotech Hunter | Biotech Hunter